Direct Healthcare Professional Communication: Nulojix (belatacept)

Letter advises that as of September 2020, the requirement to confirm available supplies before initiating treatment for new patients is expected to remain in place until the fourth quarter (4Q) of 2021.

Bristol-Myers Squibb Pharmaceuticals Ltd